CNS PHARMACEUTICALS INC (CNSP) Stock Income Statement
USA - NASDAQ:CNSP - US18978H5081 - Common Stock
7.17 USD
-0.53 (-6.88%)
| TTM (2025-6-30) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Operating Expenses | 15.58M | 14.90M | 18.87M | 15.27M | 14.49M | |||
| Research and Development | 10.15M | 9.29M | 14.10M | 9.30M | 9.81M | |||
| Selling, General, and Administrative Expenses | 5.42M | 5.61M | 4.77M | 5.97M | 4.68M | |||
| Operating Income | -15.58M | -14.90M | -18.87M | -15.27M | -14.49M | |||
| Interest Income/Expense | 117.40K | 44.10K | 13.90K | -10.00K | -10.00K | |||
| Other Income/Expense | N/A | N/A | N/A | N/A | N/A | |||
| Non Recurring Items | N/A | N/A | N/A | N/A | N/A | |||
| Income Before Taxes | -15.46M | -14.86M | -18.85M | -15.27M | -14.50M | |||
| Income Tax | N/A | 0.00 | N/A | N/A | N/A | |||
| Net Income | -15.46M | -14.86M | -18.85M | -15.27M | -14.50M | |||
| EBITDA | -15.57M | -14.90M | -18.86M | -15.26M | -14.48M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -276.72 | -466.49 | -145.01K | -305.40K | -483.33K | |||
| Non GAAP EPS | N/A | N/A | N/A | N/A | -40.50K | |||
| Statistics | ||||||||
All data in USD